185.39-1.05 (-0.56%)
At close: 4:06PM EDT
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 186.44 |
| Open | 184.75 |
| Bid | 185.40 x 800 |
| Ask | 186.29 x 1100 |
| Day's Range | 184.49 - 186.94 |
| 52 Week Range | 131.28 - 186.94 |
| Volume | 2,964,545 |
| Avg. Volume | 1,778,488 |
| Market Cap | 88.017B |
| Beta (5Y Monthly) | 0.64 |
| PE Ratio (TTM) | 49.97 |
| EPS (TTM) | 3.71 |
| Earnings Date | Aug 04, 2021 - Aug 09, 2021 |
| Forward Dividend & Yield | 1.00 (0.54%) |
| Ex-Dividend Date | Jul 20, 2021 |
| 1y Target Est | 191.60 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-12% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Insider Monkey
Hedge Funds Cashing Out Of Zoetis Inc (ZTS)
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F filings […]
- Investor's Business Daily
Small Animal-Health Stock Nabs Buyout As Elanco Looks To Challenge Zoetis
Elanco Animal Health said Wednesday it would buy Kindred Biosciences for roughly $440 million, sending KIN stock soaring.
- Barrons.com
Elanco Strikes Deal to Better Compete With Rival Zoetis in Pet Dermatology
Elanco Animal Health said it struck a $440 million deal to acquire Kindred Biosciences, a move that will bolster its drug pipeline, particularly the fast-growing pet dermatology segment.
© 2021 Verizon Media. All rights reserved.
